Valérie Calenda started her career as research scientist in Hematology and Virology at the Institut National de la Recherche Médicale (INSERM). After collaborating on a French/US research program relating to HIV at Davis University, she joined Transgene S.A., an affiliated company of Institut Mérieux, focusing on gene Therapy and immunotherapy. She then led a spin-off project in cardio-vascular therapeutic area before collaborating with a Paris based seed Venture Capital firm. Valérie also managed several biotech clinical-stage product developments within the infectious diseases and oncology disease areas, from pre-IND to Phase 2. This led her to manage both in-licensing and out-licensing activities, including global license agreement and alliance management with Hoffman La Roche, acquisition of biotech assets in Europe and in the US.
Valérie joined Mérieux Développement as a Partner in January 2010 and has focused on Venture deal flow and investments, supporting more than 8 companies since 2010. She has also been actively involved in structuring and launching M2Care, an industrial accelerator for start-ups operating in the Healthcare and Nutrition sectors.
Valérie received her PhD in Pharmacology from the University of Marseille. She holds a degree in Hematology and a B.Sc. in Biochemistry-Immunology from the University of Marseille.
Valérie Calenda currently serves as board member of:
- Amyl Therapeutics
- Proclara Biosciences